IQWiG in dialogue
Heterogeneity in benefit assessments
Institutions assessing the benefits and harms of medical interventions are often confronted with the fact that, due to their heterogeneity, studies forming the basis of the assessment can be pooled only with difficulty or not at all. This is the case, for example, when studies show different characteristics, e.g. regarding disease severity, dosage of medication, or study duration.
The meeting "IQWiG in Dialogue 2011” therefore addressed the statistical methods for examining heterogeneity, as well as the handling of heterogeneity in the assessment of the benefits and harms of interventions.
- Introduction Prof. Dr. Ralf Bender
- Pooling of studies with different characteristics Dr. Volker Vervölgyi
- IQWiG's biometric approach to heterogeneity - current status and outlook Dr. Guido Skipka
- Measures on heterogeneity in meta-analyses - critical discussion Dr. Gerta Rücker (University Clinic Freiburg)
- Examination and handling of heteregeneity in benefit assessments - an outline of the problem Dr. Sandra Janatzek (Medical Advisory Service of the German Social Health Insurance, Essen)
- Meta-analysis of rare adverse drug effects from heterogeneous clinical trials Dr. Ekkehard Glimm (Novartis Basel)
- Discussion Prof. Dr. Armin Koch (Medical School Hannover)